Cover Image
Market Research Report

Global Biosimilars Partnering 2012-2018

Published by Current Partnering, a division of Wildwood Ventures Limited Product code 712891
Published Content info 127 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Biosimilars Partnering 2012-2018
Published: October 1, 2018 Content info: 127 Pages
Description

“The Global Biosimilars Partnering Terms and Agreements 2010 to 2018” report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Biosimilars partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Biosimilars partnering contract documents
  • Top Biosimilars deals by value

“The Global Biosimilars Partnering Terms and Agreements report” provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biosimilars agreements announced in the healthcare sectors, covering:

  • Biosimilars
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope

“Global Biosimilars Partnering Terms and Agreements 2010 to 2018” is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

“Global Biosimilars Partnering Terms and Agreements 2010 to 2018” includes:

  • Trends in Biosimilars dealmaking in the biopharma industry since 2010
  • Analysis of Biosimilars deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Biosimilars deals
  • Access to over 200 Biosimilars deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active Biosimilars dealmakers since 2010
  • The leading Biosimilars partnering resources

In “Global Biosimilars Partnering Terms and Agreements 2010 to 2018”, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

“Global Biosimilars Partnering Terms and Agreements 2010 to 2018” provides the reader with the following key benefits:

  • In-depth understanding of Biosimilars deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biosimilars agreements with numerous real life case studies
  • Comprehensive access to over 200 Biosimilars deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Biosimilars deals by value since 2010
  • Identify the most active Biosimilars dealmakers since 2010
  • Detailed access to actual Biosimilars contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Biosimilars agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Contents
Product Code: CP2124

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biosimilars dealmaking

  • 2.1. Introduction
  • 2.2. Biosimilars partnering over the years
  • 2.3. Most active Biosimilars dealmakers
  • 2.4. Biosimilars partnering by deal type
  • 2.5. Biosimilars partnering by therapy area
  • 2.6. Biosimilars partnering by industry sector
  • 2.7. Deal terms for Biosimilars partnering
    • 2.7.1 Biosimilars partnering headline values
    • 2.7.2 Biosimilars deal upfront payments
    • 2.7.3 Biosimilars deal milestone payments
    • 2.7.4 Biosimilars royalty rates
  • 2.8. The anatomy of an Biosimilars deal
  • 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
  • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
  • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Biosimilars deals

  • 3.1. Introduction
  • 3.2. Top Biosimilars deals by value

Chapter 4 - Most active Biosimilars dealmakers

  • 4.1. Introduction
  • 4.2. Most active Biosimilars dealmakers
  • 4.3. Most active Biosimilars partnering company profiles

Chapter 5 - Biosimilars contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Biosimilars contracts dealmaking directory

Chapter 6 - Biosimilars dealmaking by technology type

  • Biosimilars
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Biosimilars deals by company A-Z
  • Appendix 2 - Biosimilars deals by stage of development
  • Appendix 3 - Biosimilars deals by deal type
  • Appendix 4 - Biosimilars deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES:

  • Figure 1: Biosimilars partnering since 2010
  • Figure 2: Active Biosimilars dealmaking activity sincce 2010
  • Figure 3: Biosimilars partnering by deal type since 2010
  • Figure 4: Biosimilars partnering by disease type since 2010
  • Figure 5: Biosimilars partnering by industry sector since 2010
  • Figure 6: Biosimilars deals with a headline value
  • Figure 7: Biosimilars deals with an upfront value
  • Figure 8: Biosimilars deals with a milestone value
  • Figure 9: Biosimilars deals with a royalty rate value
  • Figure 10: Top Biosimilars deals by value since 2010
  • Figure 11: Most active Biosimilars dealmakers since 2010
  • Figure 12: Biosimilars partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top